Charles Duncan

Charles Duncan

Director/Board Member at VANDA PHARMACEUTICALS INC.

Net worth: 308 345 $ as of 31/08/2026

63 year
Finance
Health Technology
Consumer Services

Profile

Charles C.
Duncan
is currently an Independent Director at Vanda Pharmaceuticals, Inc. starting in 2026, a Director at BetterLife Pharma, Inc. starting in 2026, and MD, Head-Biotech Strategy & Development at Gilmartin Group LLC.
Former positions include Managing Director & Senior Analyst at Citizens JMP Securities LLC in 2012, Biotechnology Analyst at Cantor Fitzgerald & Co. from 2018 to 2025, Senior Research Analyst at Piper Sandler & Co. from 2014 to 2018, Analyst roles at Prudential Securities, Chatfield Dean & Co., Inc., and Tucker Anthony Cleary Gull, and Principal at Dresdner Kleinwort Wasserstein Group, Inc. Education includes undergraduate studies at the University of Wisconsin and a doctorate from The University of Colorado.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
04/06/2026 57,101 ( 0.09% ) 308 345 $ 31/08/2026
02/09/2026 0 ( -.--% ) - $ 31/08/2026

Charles Duncan active positions

CompaniesPositionStart
VANDA PHARMACEUTICALS INC. Director/Board Member 22/04/2026
BETTERLIFE PHARMA INC. Director/Board Member 31/08/2026
Corporate Officer/Principal -

Former positions of Charles Duncan

CompaniesPositionEnd
Analyst-Equity 01/06/2025
Analyst-Equity 01/07/2018
Analyst-Equity 30/11/2012
Corporate Officer/Principal -
Corporate Officer/Principal -
See the detail of Charles Duncan's experience

Training of Charles Duncan

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

97

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Finance

Finance

Finance

Finance

Health Technology

Health Technology

Finance

Finance

Consumer Services

Consumer Services

Dresdner Kleinwort Wasserstein Group, Inc.

Finance

  1. Stock Market
  2. Insiders
  3. Charles Duncan